Compare Datadog Inc (DDOG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Datadog Inc vs BIO-TECHNE Corp — how do they compare? Datadog Inc trades at $251.6 (market cap $93.64B), while BIO-TECHNE Corp trades at $72.06 (market cap $11.24B). The key difference: Datadog Inc is far larger — about 8.3× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Datadog Inc pays none. Which is the better fit depends on your goals.
| DDOG | TECH | |
|---|---|---|
Market Cap | $93.64B | $11.24B |
Sector | Technology | Health |
52-Week High | $288.15 | $72.29 |
52-Week Low | $102.62 | $43.31 |
Enterprise Value | $89.93B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $233.93, up 2.02% today, but remains bearish technically with resistance near $244. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.65 versus $0.583 expected, and raised full-year revenue guidance to $4.45B-$4.47B. However, the stock faces pressure from high valuations, with a P/E of 467.86, and concerns over decelerating bookings growth from a major AI customer.
Outlook is mixed: robust revenue growth and AI momentum support long-term potential, but premium valuation and near-term usage volatility pose risks. Analyst consensus is bullish with an $288.55 price target, though insider selling and technical weakness suggest cautious near-term sentiment. Investors should balance growth prospects against execution risks and market expectations.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
